Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

N-049

Supelco

(±)-Norsertraline hydrochloride solution

100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise

Größe auswählen

1 ML
CHF 152.00

CHF 152.00

Voraussichtliches Versanddatum16. April 2025

Bulk-Bestellung anfordern
Alle Fotos(1)

Größe auswählen

Ansicht ändern
1 ML
CHF 152.00

About This Item

Empirische Formel (Hill-System):
C16H16Cl3N
CAS-Nummer:
91797-57-8
Molekulargewicht:
328.66
EG-Nummer:
200-659-6
MDL-Nummer:
MFCD08063707
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329818438
NACRES:
NA.24

CHF 152.00

Voraussichtliches Versanddatum16. April 2025

Bulk-Bestellung anfordern

Qualität

certified reference material

Qualitätsniveau

300

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

100 μg/mL in methanol (as free base)

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

N[C@H]1CC[C@@H](C2=CC(Cl)=C(Cl)C=C2)C3=C1C=CC=C3.[H]Cl

InChI

1S/C16H15Cl2N.ClH/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13;/h1-5,7,9,11,16H,6,8,19H2;1H/t11-,16-;/m0./s1

InChIKey

YKXHIERZIRLOLD-RISSCEEYSA-N

Allgemeine Beschreibung

Norsertraline is a major urinary metabolite and N-desmethyl analog of the SSRI antidepressant sertraline. Marketed under trade names such as Zoloft® and Lustral, sertraline is used to treat major depressive, obsessive-compulsive and panic and social anxiety disorders in both adults and children.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zoloft is a registered trademark of Pfizer, Inc.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

W Ross Tracey et al.
American journal of physiology. Heart and circulatory physiology, 285(6), H2780-H2787 (2003-08-16)
We recently reported the identification of a novel human adenosine A3 receptor-selective agonist, (2S,3S,4R,5R)-3-amino-5-[6-[5-chloro-2-(3-methylisoxazol-5-ylmethoxy)benzylamino]purin-9-yl]-4-hydroxytetrahydrofuran-2-carboxylic acid methylamide (CP-608,039), with 1,260-fold selectivity for the human A3 versus human A1 receptor (DeNinno et al., J Med Chem 46: 353-355, 2003). However, because the
Margareta Reis et al.
Human psychopharmacology, 19(5), 283-291 (2004-07-15)
Sertraline and paroxetine are frequently prescribed SSRIs for long-term treatment of major depression. Nevertheless, continuous follow-ups of drug concentrations prevailing in patients during the whole treatment period are not available. Hence, in a large phase IV clinical trial, a total
Frank Musshoff et al.
Archiv fur Kriminologie, 210(1-2), 51-56 (2002-10-09)
Sertraline (CAS 79617-96-2) is a relatively safe medication for patients suffering from depression. Data reporting the postmortal distribution of sertraline and desmethylsertraline remain rare as well as reports of risks of side effects following ingestion of the drug. In a
Human cytochromes mediating sertraline biotransformation: seeking attribution.
D J Greenblatt et al.
Journal of clinical psychopharmacology, 19(6), 489-493 (1999-12-10)
Zachary N Stowe et al.
The Journal of clinical psychiatry, 64(1), 73-80 (2003-02-20)
The purpose of this study was to attain a new landmark in the area of selective serotonin reuptake inhibitor therapy during lactation by establishing a basis for interpreting infant serum concentrations and for minimizing infant exposure in the absence of
Alle zugehörigen Dokumente anzeigen

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.